Delving into the Latest Updates on Perampanel with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, Perampanel Hydrate, BIOS2207

+ [7]

Target

AMPA receptor

Action

antagonists

Mechanism

AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Epilepsies, PartialEpilepsyEpilepsy, Idiopathic Generalized+ [3]

Inactive Indication

Acute migraineAmyotrophic Lateral SclerosisDiabetic Neuropathies+ [11]

Originator Organization

Active Organization

+ [4]

Inactive Organization-

License Organization

Biotoscana Investments SA

Catalyst Pharmaceuticals, Inc.

Esteve Pharmaceuticals SA

+ [2]

Drug Highest PhaseApproved

First Approval Date

European Union (23 Jul 2012),

Epilepsies, PartialEpilepsy, Idiopathic GeneralizedEpilepsy, Tonic-Clonic+ [2]

RegulationOrphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC23H15N3O

InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N

CAS Registry380917-97-5

Glioblastoma is the most common and aggressive form of brain cancer in adults. Despite surgery, radiotherapy, and chemotherapy, most patients only live about one year after diagnosis. There is an urgent need for new and better treatments.
Recent research has shown that glioblastoma cancer cells communicate with surrounding brain cells through electrical signals that help the tumor grow and resist treatment. Two existing drugs, perampanel (used for epilepsy) and senicapoc (previously tested for blood disorders), may block these harmful signals. Laboratory studies suggest that combining these two drugs could slow tumor growth and make cancer cells more sensitive to standard therapy.
The SENIPERA trial will test whether perampanel and senicapoc, alone and in combination, are safe and well tolerated when added to standard treatment for newly diagnosed glioblastoma. The study will also measure how well these drugs reach the brain and tumor, and how they affect tumor biology.
The study has two parts:
Part A: Tests different doses of senicapoc alone to find the maximum tolerable dose.
Part B: Randomly assigns patients to receive either perampanel alone or perampanel together with senicapoc.
Participants will all receive standard therapy, including surgery, radiochemotherapy, and adjuvant chemotherapy. During surgery, small samples of tumor and fluid will be collected safely to study how the drugs act in the body and how tumor cells respond. Participants will be closely monitored for side effects and followed with regular clinical visits and MRI scans.
The trial will take place at Aarhus University Hospital, Denmark, from February 2026 to November 2028 and will enroll 27-36 adult patients. The study aims to identify safe and biologically active treatment combinations that could be tested in larger trials to improve future glioblastoma care.

Start Date01 Mar 2026

Sponsor / Collaborator

Århus Universitetshospital

[+2]

JPRN-jRCT1061250057

/ RecruitingPhase 2IIT

A Single-Arm, Open-Label Phase II Study Evaluating the Antitumor Effect of Perampanel in Adult-Type Diffuse Glioma (CNS WHO Grade 2-3)

Start Date11 Oct 2025

Sponsor / Collaborator-

NCT05684978

/ TerminatedPhase 4IIT

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety. The study will recruit 25 patients at WSU. The study will last for about 96 weeks and will involve a screening visit and two in clinic visits at 3 and 6 months. If the subjects give written informed consent and meet all eligibility criteria they will be clinically evaluated and will be given the study drug. This study will involve recording of patients medical history, drug history and epilepsy history. A physical exam and a and neurological exam will also be performed to study the heath status of the participant. Results and patient information will be stored in a database for analysis to find commonality among key factors that have been seen in past research.

Start Date10 Oct 2025

Sponsor / Collaborator

Wayne State University (Michigan)

100 Clinical Results associated with Perampanel

Login to view more data

100 Translational Medicine associated with Perampanel

Login to view more data

100 Patents (Medical) associated with Perampanel

Login to view more data

1,298

Literatures (Medical) associated with Perampanel

01 May 2026·EPILEPSY & BEHAVIOR

Effect of adjunctive perampanel on daytime sleepiness and quality of life in adults with focal–onset seizures: Post hoc analyses of the AMPA study

Article

Author: Liguori, Claudio ; Chiacchiaretta, Martina ; Sáinz-Fuertes, Ricardo ; Gentile, Anna Lisa ; Assenza, Giovanni ; Patten, Anna

OBJECTIVE:

Assess the relationship between subjective daytime sleepiness and therapeutic effect of adjunctive perampanel in a post hoc analysis of AMPA (NCT04257604), a prospective, observational study in Italy.

METHODS:

AMPA included people with epilepsy (PWE) aged ≥ 12 years with insufficiently controlled focal-onset seizures, with/without focal to bilateral tonic-clonic seizures, on 1-3 baseline anti-seizure medications, who were prescribed adjunctive perampanel. Full Analysis Set (FAS) included PWE (≥ 18 years) who received ≥ 1 perampanel dose, with baseline Epworth Sleepiness Scale (ESS) scores. ESS was administered at baseline and each study visit for ≤ 12 months. Excessive daytime sleepiness was defined as ESS ≥‍ 11 points. Quality of life (QoL) was assessed using QOLIE-31-P.

RESULTS:

FAS included 202 PWE. Mean (SD) ESS was 6.3 (4.5) at baseline (N = 202) and 6.2 (4.4) at end of treatment (EoT; n = 177); 29 PWE reported ≥‍ 4-point decreases from baseline ESS at EoT, while 31 reported ≥‍ 4-point increases. Median percent reductions in seizure frequency/28 days from baseline were 85.6% in improved ESS group and 77.6% in worsened ESS group (n = 14 each). At EoT, 14 PWE with no excessive daytime sleepiness reported a mean (SD) QOLIE-31-P score change of + 7.9 (12.9) points while 11 PWE with excessive daytime sleepiness had a mean (SD) change of -3.4 (18.6). Overall incidence of treatment-emergent adverse events was 56.9%; most commonly, dizziness/vertigo (22.8%) and somnolence (8.4%).

CONCLUSION:

In the FAS, adjunctive perampanel did not worsen daytime sleepiness for ≤ 12 months. In a small subset of patients, seizure frequency was reduced, regardless of ESS changes, and mean QoL at EoT was improved for those without excessive daytime sleepiness but declined for those with excessive daytime sleepiness. No new safety signals emerged.

01 Apr 2026·BIOMEDICAL CHROMATOGRAPHY

Therapeutic Drug Monitoring of Clobazam, Perampanel, and Lacosamide Using a UPLC‐MS/MS Method: Analysis of 5‐Year Experience in a Large Cohort of Pediatric Epilepsy Patients From China

Article

Author: Lu-Hai Yu ; Yan Sun ; Hong-Jian Li ; Jing Yu ; Hui-Lan Zhang ; Ting Zhao ; Jie Feng

ABSTRACT:

This study aims to develop an ultra high‐performance liquid chromatography–mass spectrometry (UPLC‐MS/MS) method to quantify clobazam, perampanel, and lacosamide plasma concentrations in pediatric epilepsy patients. Elution was performed using a gradient elution program, with a mobile phase composed of 0.01% formic acid in water and 0.01% formic acid in acetonitrile. The flow rate was 0.6 mL/min. The injector temperature was 10°C. The injection volume was 4 μL. Linearity, sensitivity, precision, accuracy, specificity, carryover, and extraction recovery were evaluated. Therapeutic drug monitoring data of 1132 samples were analyzed. The method was linear within 10–600 ng/mL, 100–2000 ng/mL, and 1.0–30.0 μg/mL for clobazam, perampanel, and lacosamide, respectively ( r ≥ 0.998). The results indicated that the within‐run and between‐run precision coefficient of variation (CV %) did not exceed 15.0%, and that the accuracy (bias) ranged from −8.3% to 13.6%. Recovery ranged from 90.9% to 108.1%. All plasma samples could be maintained for up to 3 h at ambient temperature, 24 h at 4°C, 30 days at −30°C, and after successive freeze–thaw cycles in the absence of significant degradation. We successfully developed a simple and rapid LC‐MS/MS method for the simultaneous measurement of three new generation ASMs, and successfully applied it to clinical practice.

01 Mar 2026·BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Pharmacokinetics of Perampanel in Danish Paediatric Patients With Epilepsy Based on Therapeutic Drug Monitoring

Article

Author: Angelucci, Sara ; Shorter, John R. ; Hansen, Maja Stjerne ; Houlind, Morten Baltzer ; Bayat, Allan ; Hansen, Anne Forsingdal Højte

ABSTRACT:

We aimed to quantify inter‐ and intra‐patient variability in serum perampanel concentrations and assess whether concentrations predict efficacy or tolerability. We conducted a retrospective cohort study of 68 children and adolescents (< 18 years) treated at the Danish Epilepsy Centre (2017–2024), analysing 311 TDM samples. Dose‐normalized concentration ratio was summarized as the concentration‐to‐dose‐per‐kilogram ratio (C:(D/kg)) and evaluated by age group and co‐medication category: enzyme‐inducing anti‐seizure medications (ASMs), valproate or non‐inducing ASMs. Clinical outcomes were change in seizure burden, seizure freedom and adverse effects. Perampanel concentrations were outside the recommended therapeutic range in 13.8% of samples, and C:(D/kg) varied 59.2‐fold across patients. Children < 6 years had lower concentration than adolescents > 12 years, and enzyme‐inducing ASMs markedly reduced C:(D/kg). Overall, 80.9% of patients had reduced seizure burden, and 20.6% became seizure‐free, but serum concentrations did not correlate with seizure freedom or adverse effects. TDM is valuable for detecting under‐ or over‐dosing caused by age‐related clearance changes or enzyme‐inducing co‐medications. While dose adjustments can be guided by serum concentrations, optimization should ultimately target clinical seizure reduction and tolerability.

83

News (Medical) associated with Perampanel

07 May 2026

·firstwordpharma.com

Angelini to acquire Catalyst in $4.1B deal, marking US entry

Angelini Pharma is set to acquire rare disease-focused Catalyst Pharmaceuticals for approximately $4.1 billion (€3.5 billion) — marking the Italian pharma's first foray into the US commercial market.The deal announced Thursday will see Angelini buying all outstanding shares of Catalyst at $31.50 apiece, representing a 21% premium over the latter's closing share price on Apr. 22.The acquisition provides a significant boost to Angelini portfolio, by gaining Catalyst's three FDA-approved therapies — Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome, Agamree (vamorolone) for Duchenne muscular dystrophy and Fycompa (perampanel) for epilepsy, whose US rights were acquired from Eisai in 2023.The transaction will help "establish Angelini…as a relevant global player in neurological rare diseases," said Sergio Marullo di Condojanni, chief executive of Angelini. "Entering the US market will allow us to acquire the scale and capabilities needed to continue this journey."Angelini Pharma intends to integrate Catalyst's commercial infrastructure with its own European portfolio — which includes the epilepsy treatment Ontozry (cenobamate) — to develop what it describes as a next-generation therapeutic platform in rare diseases.More to follow…

AcquisitionDrug Approval

07 May 2026

·allsci.com

Angelini Pharma acquires Catalyst Pharmaceuticals for USD 4.1b to enter US market, expand rare disease portfolio

Italy-based Angelini Pharma S.p.A. has entered into a definitive agreement to acquire Catalyst Pharmaceuticals (Nasdaq: CPRX) for USD 31.50 per share in cash, representing a total equity value of approximately USD 4.1 billion (EUR 3.5 billion). The transaction marks Angelini Pharma’s entry into the US market and is structured to consolidate its rare neurological and neuromuscular disease portfolio alongside an established US commercial infrastructure. Under the deal terms, an Angelini subsidiary will merge with and into Catalyst, with Catalyst surviving as a wholly owned subsidiary post-close. The USD 31.50 per share price represents a 28% premium to the 30-day volume-weighted average trading price to that date. Angelini expects to finance the acquisition through a combination of cash and debt, with BNP Paribas acting as Sole Global Coordinator and Underwriter of the financing package. Blackstone funds and select international partners are participating in the transaction. Closing is expected in Q3 2026, subject to Catalyst stockholder approval, required regulatory clearances, and other customary conditions. Catalyst’s disclosed portfolio centers on three FDA-approved products targeting rare neuromuscular and neurological indications. Firdapse (amifampridine), a voltage-gated potassium channel blocker, holds FDA approval as the only evidence-based treatment for Lambert-Eaton myasthenic syndrome in patients aged six and above. Agamree (vamorolone), a dissociative corticosteroid with a modified steroid backbone designed to reduce glucocorticoid-associated side effects, received FDA approval in 2023 for Duchenne muscular dystrophy in patients aged two and above, with Catalyst holding North American rights. Fycompa (perampanel), an AMPA receptor antagonist approved for partial-onset seizures and primary generalized tonic-clonic seizures, rounds out the portfolio through US rights acquired from Eisai. The geographic scope of the transaction is therefore primarily US-centric, with North American rights to Agamree representing the broadest territorial coverage of any single acquired asset. In a comparable transaction, UCB acquired Zogenix for approximately USD 1.9 billion in 2022, deploying a structurally similar rationale — a European CNS-focused acquirer absorbing a US-listed commercial-stage rare disease company with an FDA-approved rare neurological therapy to gain US scale. The Angelini Pharma acquisition of Catalyst Pharmaceuticals operates on a larger financial basis and broader product scope, but shares the same cross-Atlantic strategic logic of using a US commercial footprint as the primary value driver alongside the approved asset portfolio itself. Separately, Catalyst announced the resolution of patent litigation brought in response to an Abbreviated New Drug Application filed on behalf of Hetero USA, Inc. seeking approval to market a generic version of Firdapse prior to expiration of applicable patents. Catalyst and its licensor SERB S.A. entered into a settlement agreement with Hetero, terminating all ongoing patent litigation pending in the US District Court for the District of New Jersey. The confidential settlement agreement will be submitted to the US Federal Trade Commission and the US Department of Justice for review as required by law. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

07 May 2026

·www.biospace.com

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD per share in cash, for a total equity value of approximately 4.1 billion USD (equivalent to 3.5 billion euros) which represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information, as well as a 28% premium to the 30-day volume-weighted average trading price to that unaffected date. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026. This acquisition marks a pivotal moment in the Angelini Group’s history — a group with over 100 years of history, chaired by Thea Paola Angelini, a fourth-generation member of the Angelini family — led by Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Pharma. The transaction will be carried out with the participation of Blackstone funds and select international partners, and will be financed with the support of BNP Paribas, acting as Sole Global Coordinator and Underwriter of the financing package. Founded in 2002 and listed on Nasdaq since 2006, Catalyst has built a robust portfolio of products focused on the treatment of rare neuromuscular and neurological diseases: FIRDAPSE ® (amifampridine), the only evidence-based treatment approved by the U.S. Food and Drug Administration (FDA) for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged six and above; AGAMREE ® (vamorolone) a novel corticosteroid approved by the FDA in 2023 for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 and above; and FYCOMPA ® (perampanel), an antiepileptic drug approved for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures, the U.S. rights to which were acquired from Eisai in 2023. Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst’s portfolio and exceptional commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. This transaction reinforces the commitment Angelini Pharma has built over recent years through products such as Ontozry ® and high-pro collaborations. Catalyst's portfolio is expected to significantly strengthen the company's strategic objectives, growing its presence in the U.S. as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe. Angelini Pharma’s continued industrial presence in Italy will remain a strategic asset as a valuable production and scientific center within the combined company's global operations. Sergio Marullo di Condojanni, CEO of Angelini Pharma , commented: " Five years ago, we embarked on a profound transformation of Angelini Pharma — organizational, scientific and strategic — with the ambition to build a company capable of competing at the highest global level. On one hand, we continued to invest in our traditional portfolio; on the other, we chose to focus on central nervous system disorders, with the goal of addressing an unmet medical need that is, unfortunately, growing significantly. We invested in innovation through the development of a high-value asset pipeline, including collaborations with leading partners such as Blackstone Life Sciences in GRIN Therapeutics. Today, we take another significant step with the acquisition of Catalyst Pharmaceuticals, which we believe will establish Angelini Pharma as a relevant global player in neurological Rare Diseases. Entering the U.S. market will allow us to acquire the scale and capabilities needed to continue this journey. Patient care remains at the heart of our vision. We continue to look ahead with determination, backed by a clear strategy and the drive to keep growing on a global scale. We are proud of a transaction that demonstrates, once again, the dynamism of the Italian pharmaceutical industry.” Rich Daly, President and CEO of Catalyst , commented: “This is a pivotal and transformative moment for Catalyst, our team, and the patients we serve. By combining our unique capabilities in rare diseases with Angelini’s proven global reach, we will create a stronger, scalable, and robust rare disease platform to expand access to life-changing therapies worldwide. For shareholders, this transaction delivers immediate and certain cash value through a compelling premium. We are proud of the incredible foundation our team has built and are confident that together with Angelini, we can enhance patient support, accelerate innovation, and continue to drive sustainable long-term value for all stakeholders.” Media Contacts Angelini Pharma Roberto Scrivo Chief External Affairs Communication & Sustainability Officer +39 348 454 6502 Roberto.scrivo@angelinipharma.com Chiara Antoniucci Global External & Internal Communication Director +39 347 713 3926 chiara.antoniucci@angelinipharma.com Federica Marcelli Italy Media Communications Manager +39 3383924138 federica.marcelli@angelinipharma.com Media Jemini Sedani Real Chemistry, Group Director, Media & Engagement +44 (0)7940 594788 jsedani@realchemistry.com Catalyst Investors Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Jed Repko / Mahmoud Siddig Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

Drug ApprovalAcquisition

100 Deals associated with Perampanel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Perampanel	N03AX22	DB08883

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Epilepsies, Partial	European Union	Eisai GmbH	23 Jul 2012
Epilepsies, Partial	Iceland	Eisai GmbH	23 Jul 2012
Epilepsies, Partial	Liechtenstein	Eisai GmbH	23 Jul 2012
Epilepsies, Partial	Norway	Eisai GmbH	23 Jul 2012
Epilepsy	European Union	Eisai GmbH	23 Jul 2012
Epilepsy	Iceland	Eisai GmbH	23 Jul 2012
Epilepsy	Liechtenstein	Eisai GmbH	23 Jul 2012
Epilepsy	Norway	Eisai GmbH	23 Jul 2012
Epilepsy, Idiopathic Generalized	European Union	Eisai GmbH	23 Jul 2012
Epilepsy, Idiopathic Generalized	Iceland	Eisai GmbH	23 Jul 2012
Epilepsy, Idiopathic Generalized	Liechtenstein	Eisai GmbH	23 Jul 2012
Epilepsy, Idiopathic Generalized	Norway	Eisai GmbH	23 Jul 2012
Epilepsy, Tonic-Clonic	European Union	Eisai GmbH	23 Jul 2012
Epilepsy, Tonic-Clonic	Iceland	Eisai GmbH	23 Jul 2012
Epilepsy, Tonic-Clonic	Liechtenstein	Eisai GmbH	23 Jul 2012
Epilepsy, Tonic-Clonic	Norway	Eisai GmbH	23 Jul 2012
Secondarily generalized seizures	European Union	Eisai GmbH	23 Jul 2012
Secondarily generalized seizures	Iceland	Eisai GmbH	23 Jul 2012
Secondarily generalized seizures	Liechtenstein	Eisai GmbH	23 Jul 2012
Secondarily generalized seizures	Norway	Eisai GmbH	23 Jul 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lennox Gastaut Syndrome	Phase 3	United States	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	Japan	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	Australia	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	Belgium	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	Czechia	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	India	Eisai, Inc.	13 Dec 2016
Lennox Gastaut Syndrome	Phase 3	South Korea	Eisai, Inc.	13 Dec 2016
Seizures	Phase 3	United States	Eisai, Inc.	30 Apr 2008
Seizures	Phase 3	Argentina	Eisai, Inc.	30 Apr 2008
Seizures	Phase 3	Brazil	Eisai, Inc.	30 Apr 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04257604 (AMPA, Pubmed \| Epilepsy Behav)	Not Applicable	Seizures	202	Perampanel	prnqxeiavp(pduojhlhis) = pxcybrrhjh jktajduqvk (oczuhtlfyl ) View more	Positive	01 May 2026
P9-9.015 (AAN2025)	Not Applicable	Excessive Daytime Sleepiness	207	Clonazepam	ecrnsioyuq(vazheuufmo) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. lemxbvzwwh (ygvytwyvkt )	Positive	07 Apr 2025
				Levetiracetam
NCT04497142 (CTgov)	Phase 1/2	Seizures \| High grade glioma	12	Perampanel (Perampanel + Electrocorticography)	sdgpxvuekp(brbjpmitza) = hgivmkrfxn knvyjmoumw (lfpgraider, nqjsgesxcc - lfvyijeise) View more	-	05 Aug 2024
				Levetiracetam (Standard of Care + Electrocorticography)	sdgpxvuekp(brbjpmitza) = kxodyrbuaw knvyjmoumw (lfpgraider, bnnysjnkef - lhpnmaupwe) View more
NCT05201703 (CTgov)	Phase 4	Epilepsy	7	Fycompa (Fycompa 4 mg Daily)	mpvnsinfoj = huwgbdasax dovwexqgcw (ccywdkmdtg, huualbodff - tvyswewdca) View more	-	31 Jul 2024
				Fycompa with a boost (Fycompa 4 mg Daily With a Boost to 6 mg Daily)	mpvnsinfoj = fdhgefogcu dovwexqgcw (ccywdkmdtg, lzxiqqjzbs - xnqfphdepi) View more
EAN2024	Not Applicable	Pregnancy, Prolonged	56	Perampanel	zymgkovxqu(ypsorvnilp) = reported by 14 subjects kwrzngzuqj (dzcetynkzk )	Positive	28 Jun 2024
NCT04202159 (PERPRISE, EAN2024)	Not Applicable	Seizures	183	Perampanel as add-on therapy	ilmrlparyl(pgjnlvutoy) = gzzkzxdard iphzrywyxx (ceqwmnnple ) View more	Positive	28 Jun 2024
				Perampanel as substitution therapy	ilmrlparyl(pgjnlvutoy) = midppowkto iphzrywyxx (ceqwmnnple ) View more
NCT04417907 (CTgov)	Phase 4	Epilepsy	29	Placebo (Placebo)	bohpvurduh(imqkixfiik) = lkyhvqhosk rehctqzcsc (ivnjenwstl, 1.00) View more	-	06 Jun 2024
				Perampanel 1 week titration (PER 1 Week Titration)	bohpvurduh(imqkixfiik) = uaxgoeztgl rehctqzcsc (ivnjenwstl, .55) View more
CNS2023	Phase 4	-	297	Perampanel	ypqfnhqjtq(opwznaseoi) = 4.9% bfrydwqajz (hzeizkerfz ) View more	Positive	01 Oct 2023
IEC2023	Not Applicable	Epilepsy, Generalized	-	Perampanel	yhhpyggzet(pwbzrtbcdl) = xlitkzwlmz xkjpmnlwsc (gpvieochtn ) View more	-	04 Sep 2023
PERMIT, PROVE (IEC2023)	Phase 4	-	324	Perampanel	pugcribmzk(asknihhtty) = 4.9% qehomxifeo (gwnlfrbfpq ) View more	Positive	04 Sep 2023